SCHEMBL8737697

SCHEMBL8737697

CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2nc(-c3sc(N)nc3C)cs2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 16/20 0.66
KMT2A Q03164 16/20 0.66
MAPT P10636 15/20 0.66
GAA P10253 12/20 0.66
ALDH1A1 P00352 10/20 0.66
HSD17B10 Q99714 4/20 0.66
TDP1 Q9NUW8 4/20 0.66
PDE5A O76074 1/20 0.61
PDE1A P54750 1/20 0.61
PDE1B Q01064 1/20 0.61
PDE1C Q14123 1/20 0.61
MAPK1 P28482 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
KDM4E B2RXH2 7/20 0.51
SMN1; SMN2 Q16637 7/20 0.51
HTT P42858 6/20 0.51
LMNA P02545 5/20 0.51
USP2 O75604 2/20 0.51
TSHR P16473 2/20 0.50
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6114000 0.99 MEN1 (0.65) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8737777 0.89 MEN1 (0.70) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL6114334 0.87 MMP9 (0.65) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8737789 0.87 MEN1 (0.73) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8738018 0.87 MEN1 (0.73) MEN1KMT2AMAPTGAAALDH1A1
Bromide SCHEMBL6114191 0.86 MEN1 (0.71) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8737946 0.81 MEN1 (0.82) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8739499 0.81 MEN1 (0.82) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8737699 0.81 MAPT (0.71) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL8737959 0.81 MAPT (0.70) MEN1KMT2AMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MEN1 2298/4885KMT2A 2435/4885MAPT 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.